PMID- 38153168
OWN - NLM
STAT- MEDLINE
DCOM- 20240429
LR  - 20240429
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 42
IP  - 4
DP  - 2024 Apr
TI  - Relapse in patients with antineutrophil cytoplasmic antibody-associated 
      vasculitis undergoing dialysis: a single-centre retrospective study in South 
      Korea.
PG  - 828-833
LID - 10.55563/clinexprheumatol/4ft2u1 [doi]
AB  - OBJECTIVES: The disease activity of antineutrophil cytoplasmic 
      antibody-associated vasculitis (AAV) can decrease after dialysis, and relapse 
      after dialysis is not well-studied. We investigated the clinical manifestations 
      and factors associated with relapse in patients with AAV undergoing dialysis. 
      METHODS: This retrospective study included data of patients with AAV undergoing 
      dialysis due to renal involvement from July 2005 to March 2021 in a single 
      tertiary centre in Seoul, Korea. Cox regression analysis was performed to 
      identify relapse-associated factors. RESULTS: The study cohort included 38 
      patients with a median age of 64.0 years; 28 (73.7%) were female, and 35 (92.1%) 
      patients were diagnosed with microscopic polyangiitis (MPA). At diagnosis, the 
      mean Birmingham vasculitis activity score (BVAS) was 18.3 and 66.3% of the 
      patients exhibited pulmonary manifestations. During follow-up, 12 patients 
      experienced AAV relapse, including nine patients with diffuse alveolar 
      haemorrhage (DAH), two patients with aggravated interstitial lung disease, and 
      one patient with DAH accompanied with neuropathy. Clinical features including 
      age, sex, and baseline BVAS did not significantly differ between the relapse and 
      non-relapse groups. By univariable analysis, lung infiltration, DAH, 
      corticosteroid pulse therapy for induction, and mean corticosteroid dose were 
      significantly associated with relapse. Multivariable analysis revealed that DAH 
      (adjusted hazard ratio 5.509, 95% CI 1.569-19.339; P=0.008) and mean 
      corticosteroid dose (adjusted hazard ratio 1.381, 95% CI 1.161-1.642; P<0.001) 
      were significantly associated with relapse. CONCLUSIONS: In patients with AAV 
      undergoing dialysis, DAH and mean corticosteroid dose were significantly 
      associated with relapse, highlighting the importance of close monitoring.
FAU - Lee, Yeo-Jin
AU  - Lee YJ
AD  - Department of Rheumatology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Republic of Korea.
FAU - Ahn, Soo-Min
AU  - Ahn SM
AD  - Department of Rheumatology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Republic of Korea.
FAU - Oh, Ji-Seon
AU  - Oh JS
AD  - Department of Information Medicine, Big Data Research Center, Asan Medical 
      Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
FAU - Kim, Yong-Gil
AU  - Kim YG
AD  - Department of Rheumatology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Republic of Korea.
FAU - Lee, Chang-Keun
AU  - Lee CK
AD  - Department of Rheumatology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Republic of Korea.
FAU - Yoo, Bin
AU  - Yoo B
AD  - Department of Rheumatology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Republic of Korea.
FAU - Hong, Seokchan
AU  - Hong S
AD  - Department of Rheumatology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Republic of Korea. medivineluke@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20231228
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
SB  - IM
MH  - Humans
MH  - Female
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - *Recurrence
MH  - *Renal Dialysis/adverse effects
MH  - Aged
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated 
      Vasculitis/therapy/complications/diagnosis
MH  - Republic of Korea/epidemiology
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Hemorrhage/etiology
MH  - Time Factors
EDAT- 2023/12/28 12:42
MHDA- 2024/04/29 13:58
CRDT- 2023/12/28 08:02
PHST- 2023/07/09 00:00 [received]
PHST- 2023/10/23 00:00 [accepted]
PHST- 2024/04/29 13:58 [medline]
PHST- 2023/12/28 12:42 [pubmed]
PHST- 2023/12/28 08:02 [entrez]
AID - 20150 [pii]
AID - 10.55563/clinexprheumatol/4ft2u1 [doi]
PST - ppublish
SO  - Clin Exp Rheumatol. 2024 Apr;42(4):828-833. doi: 
      10.55563/clinexprheumatol/4ft2u1. Epub 2023 Dec 28.